{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:29:23Z","timestamp":1795145363893,"version":"4.10.3"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>BK polyomavirus (BKPyV) remains a significant cause of graft dysfunction and failure in kidney transplant recipients, with DNAemia affecting up to 30% and nephropathy contributing to approximately 7% of graft losses. This review synthesizes current understanding of BKPyV pathogenesis, risk factors, and management strategies. Screening protocols and immunosuppression reduction remain the cornerstone of care, although emerging therapies\u2014including monoclonal antibodies and virus-specific T-cell therapies\u2014offer promise. The role of mammalian target of rapamycin inhibitors and other agents is critically evaluated, with recent trials challenging their efficacy. Unique transplant-related factors, such as ureteral stent use and the kidney's role as a viral reservoir, may explain the predominance of BKPyV in renal transplantation. This review highlights the need for improved serologic and cellular immunity assays, targeted antiviral therapies, and individualized approaches to retransplantation. Continued research is essential to reduce the burden of BKPyV-associated nephropathy and improve long-term kidney transplant outcomes.<\/jats:p>","DOI":"10.34067\/kid.0000000967","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T16:00:36Z","timestamp":1755619236000},"page":"2257-2262","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["BK Nephropathy in the Modern Era"],"prefix":"10.34067","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-9338","authenticated-orcid":false,"given":"David","family":"Wojciechowski","sequence":"first","affiliation":[{"name":"UT Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7320-2234","authenticated-orcid":false,"given":"Camille Nelson","family":"Kotton","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"9","key":"B1-20260109","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1097\/TP.0000000000004976","article-title":"The second international consensus guidelines on the management of BK polyomavirus in kidney transplantation","volume":"108","author":"Kotton","year":"2024","journal-title":"Transplantation."},{"issue":"3","key":"B2-20260109","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1600-6143.2005.00742.x","article-title":"Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction","volume":"5","author":"Brennan","year":"2005","journal-title":"Am J Transplant."},{"issue":"10","key":"B3-20260109","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.TP.0000156165.83160.09","article-title":"Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations","volume":"79","author":"Hirsch","year":"2005","journal-title":"Transplantation."},{"issue":"7","key":"B4-20260109","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMoa020439","article-title":"Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients","volume":"347","author":"Hirsch","year":"2002","journal-title":"N Engl J Med."},{"issue":"1","key":"B5-20260109","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-6143.2012.04320.x","article-title":"Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study","volume":"13","author":"Hirsch","year":"2013","journal-title":"Am J Transplant."},{"issue":"1","key":"B6-20260109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-3062.2008.00342.x","article-title":"Prospective monitoring of BK virus replication in renal transplant recipients","volume":"11","author":"Koukoulaki","year":"2009","journal-title":"Transpl Infect Dis."},{"issue":"2","key":"B7-20260109","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant."},{"issue":"5 Pt 1","key":"B8-20260109","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1600-6143.2006.01296.x","article-title":"Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN)","volume":"6","author":"Wadei","year":"2006","journal-title":"Am J Transplant."},{"issue":"10","key":"B9-20260109","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1681\/ASN.0000000000000457","article-title":"Neutralizing antibodies targeting BK polyomavirus: clinical importance and therapeutic potential for kidney transplant recipients","volume":"35","author":"Helle","year":"2024","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"B10-20260109","doi-asserted-by":"crossref","first-page":"e13528","DOI":"10.1111\/ctr.13528","article-title":"BK polyomavirus in solid organ transplantation-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Hirsch","year":"2019","journal-title":"Clin Transplant."},{"issue":"9","key":"B11-20260109","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/j.1600-6143.2009.02729.x","article-title":"Screening to prevent polyoma virus nephropathy in kidney transplantation: a cost analysis","volume":"9","author":"Smith","year":"2009","journal-title":"Am J Transplant."},{"issue":"2","key":"B12-20260109","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1600-6143.2009.02952.x","article-title":"BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results","volume":"10","author":"Hardinger","year":"2010","journal-title":"Am J Transplant."},{"issue":"1","key":"B13-20260109","doi-asserted-by":"crossref","first-page":"e13993","DOI":"10.1111\/tid.13993","article-title":"Development of de novo donor-specific antibodies in renal transplant recipients with BK viremia managed with immunosuppression reduction","volume":"25","author":"Hod-Dvorai","year":"2023","journal-title":"Transpl Infect Dis."},{"issue":"1","key":"B14-20260109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350701200104","article-title":"Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones","volume":"12","author":"Ali","year":"2007","journal-title":"Antivir Ther."},{"issue":"7","key":"B15-20260109","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.2215\/CJN.08261109","article-title":"Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation","volume":"5","author":"Gabardi","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"B16-20260109","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/TP.0b013e31826ec74e","article-title":"Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year","volume":"94","author":"Wojciechowski","year":"2012","journal-title":"Transplantation."},{"issue":"20","key":"B17-20260109","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/jama.2014.14721","article-title":"Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial","volume":"312","author":"Knoll","year":"2014","journal-title":"JAMA."},{"issue":"3","key":"B18-20260109","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2215\/CJN.04230413","article-title":"Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial","volume":"9","author":"Lee","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"B19-20260109","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2215\/CJN.03930907","article-title":"Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients","volume":"3","author":"Leca","year":"2008","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B20-20260109","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/ajt.13083","article-title":"Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK","volume":"15","author":"Randhawa","year":"2015","journal-title":"Am J Transplant."},{"issue":"5","key":"B21-20260109","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ajt.2023.11.007","article-title":"Preemptive intravenous human immunoglobulin G suppresses BK polyomavirus replication and spread of infection in vitro","volume":"24","author":"Sato","year":"2024","journal-title":"Am J Transplant."},{"issue":"11","key":"B22-20260109","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ajt.2024.07.002","article-title":"Nonclinical and clinical characterization of MAU868, a novel human-derived monoclonal neutralizing antibody targeting BK polyomavirus VP1","volume":"24","author":"Abend","year":"2024","journal-title":"Am J Transplant."},{"issue":"5","key":"B24-20260109","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1681\/ASN.0000000000000329","article-title":"Posoleucel in kidney transplant recipients with BK viremia: multicenter, randomized, double-blind, placebo-controlled phase 2 trial","volume":"35","author":"Chandraker","year":"2024","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"B25-20260109","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/TP.0b013e31819cc383","article-title":"An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States","volume":"87","author":"Dharnidharka","year":"2009","journal-title":"Transplantation."},{"issue":"4","key":"B26-20260109","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/TP.0000000000000890","article-title":"Risk factors for BK polyoma virus treatment and association of treatment with kidney transplant failure: insights from a paired kidney analysis","volume":"100","author":"Thangaraju","year":"2016","journal-title":"Transplantation."},{"issue":"7","key":"B27-20260109","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B28-20260109","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.transproceed.2017.06.030","article-title":"Mycophenolate mofetil withdrawal with conversion to everolimus to treat BK virus infection in kidney transplant recipients","volume":"49","author":"Wojciechowski","year":"2017","journal-title":"Transplant Proc."},{"issue":"2","key":"B29-20260109","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.kint.2024.09.018","article-title":"Insights from the BKEVER trial comparing everolimus versus mycophenolate mofetil for BK polyomavirus infection in kidney transplant recipients","volume":"107","author":"Caillard","year":"2025","journal-title":"Kidney Int."},{"issue":"3","key":"B30-20260109","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/ajt.13541","article-title":"BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12","volume":"16","author":"Hirsch","year":"2016","journal-title":"Am J Transplant."},{"issue":"10","key":"B31-20260109","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1600-6143.2010.03265.x","article-title":"Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy","volume":"10","author":"Egli","year":"2010","journal-title":"Am J Transplant."},{"issue":"3","key":"B32-20260109","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.trre.2015.02.004","article-title":"The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: a systematic review","volume":"29","author":"Viswesh","year":"2015","journal-title":"Transplant Rev (Orlando)."},{"issue":"7","key":"B33-20260109","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/j.transproceed.2011.06.034","article-title":"Ureteral stents: a risk factor for polyomavirus BK viremia in kidney transplant recipients undergoing protocol screening","volume":"43","author":"Siparsky","year":"2011","journal-title":"Transplant Proc."},{"key":"B34-20260109","doi-asserted-by":"crossref","first-page":"459747","DOI":"10.1155\/2014\/459747","article-title":"Ureteral stent placement increases the risk for developing BK viremia after kidney transplantation","volume":"2014","author":"Hashim","year":"2014","journal-title":"J Transplant."},{"issue":"2","key":"B35-20260109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/tri.12888","article-title":"Ureteral stent placement and immediate graft function are associated with increased risk of BK viremia in the first year after kidney transplantation","volume":"30","author":"Maliakkal","year":"2017","journal-title":"Transplant Int."},{"issue":"6","key":"B36-20260109","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/TP.0000000000001261","article-title":"Correlation of BK virus neutralizing serostatus with the incidence of BK viremia in kidney transplant recipients","volume":"101","author":"Abend","year":"2017","journal-title":"Transplantation."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:59:43Z","timestamp":1786478383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000967"}},"subtitle":["What Have We Learned?"],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000967","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]}}}